Tegoprubart - Eledon Pharmaceuticals
Alternative Names: Anti-CD40 ligand monoclonal antibody - ALS Therapy Development Institute/Eledon Pharmaceuticals; Anti-CD40 ligand monoclonal antibody - Eledon Pharmaceuticals; Anti-CD40L - ALS Therapy Development Institute; AT-1501Latest Information Update: 06 Sep 2024
At a glance
- Originator ALS Therapy Development Institute
- Developer Eledon Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; Renal transplant rejection
- Phase I/II Islet cell transplant rejection
- Phase I Xenotransplant rejection
- Preclinical Liver transplant rejection
- No development reported Autoimmune disorders
- Discontinued Allotransplant rejection; IgA nephropathy
Most Recent Events
- 05 Sep 2024 Eledon Pharmaceuticals completes enrolment in phase-I/II clinical trials in Renal transplant rejection (Prevention) in US, Australia, France, Germany, Spain, Brazil and Canada (IV) (NCT05983770)
- 07 May 2024 Adverse events and efficacy data from a phase Ib Renal transplant rejection released by Eledon Pharmaceuticals
- 04 Apr 2024 Discontinued - Phase-II for IgA nephropathy (In the elderly, In adults) in Philippines, Poland, Sri Lanka, United Kingdom, Croatia, Thailand (IV)